Omeprazol Tiostene Laboratórios Azevedos Indústria Farmacêutica (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Tiostene Laboratórios Azevedos Indústria Farmacêutica, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑esophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazol Tiostene Laboratórios Azevedos Indústria Farmacêutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Omeprazole is a proton pump inhibitor that acts on gastric acid secretion pathways. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the esophageal lining. - Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder. - Helicobacter pylori eradication regimens (as part of combination therapy): enhances the effectiveness of antibiotic treatment by reducing gastric acidity. - Erosive esophagitis: aids in mucosal healing and symptom control.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or abdominal discomfort: transient gastrointestinal upset. - Flatulence: excess gas formation. - Constipation: occasional bowel habit changes. - Dry mouth: reduced salivary flow.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures (with long‑term use): increased risk of hip, wrist or spine fractures. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin detachment.

Before initiating omeprazole therapy, consider the following precautions: - Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review long‑term use: prolonged therapy has been linked to nutrient malabsorption and fracture risk. - Evaluate concomitant medications: potential for altered absorption of drugs that require an acidic environment. - Monitor for infection: increased susceptibility to gastrointestinal infections such as C. difficile. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular event risk. - Atazanavir and other protease inhibitors: markedly decreased antiviral exposure. - Methotrexate (high dose): increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent monitoring. - Digoxin: elevated serum levels may occur, necessitating dose adjustment. - Diazepam: increased sedation risk due to higher plasma concentrations.